Canterbury DHB
Due to increasing evidence about the differences in outcome based on timing of diagnosis, the 2016 WHO classification of haematopietic malignancies emphasizes the differences between pre-fibrotic/early phase PMF (median survival >15 years) and overt phase PMF (median survival 3–7 years), see Rumi E, et al. (2017),1 table 2, page 3.
A bone marrow biopsy is important in this classification, especially in distinguishing between PMF and ET. A condition similar to PMF can develop in patients with pre-existing PV or ET (see Polycythaemia Vera and Essential Thrombocythaemia). Exclude secondary causes before diagnosing primary myelofibrosis.
Topic Code: 6242